Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid

Efficacy and Biocompatibility of Neutral Icodextrin Peritoneal Dialysis Fluid.

Neutral icodextrin peritoneal dialysis (PD) fluid (n-ICO) has become available for use in Japan. However, removal of water and solutes remains to be elucidated in detail. The present study was designed to determine removal of water, electrolytes, and small, middle, and large molecules in a period of 16 hours. In addition, biocompatibility with respect to peritoneal mesothelial cells was determi...

Icodextrin and spurious hyperglycemia in peritoneal dialysis patients: a hospital-wide attempt to prevent such errors

is infused into the peritoneal cavity, and toxic materials are removed by ultrafiltration and diffusive clearance through the peritoneal membrane. PD is used in 2.9% of the approximately 320,000 patients regularly undergoing any form of hemodialysis in Japan. Recently, a non-absorbable carbohydrate (icodextrin; Extraneal; Baxter Healthcare, Chicago, IL, USA) has been introduced for PD, and more...

Clinical effects of icodextrin in peritoneal dialysis

Objective. This study reviews the relevant publications on the clinical effects of icodextrin in peritoneal dialysis (PD). Design. The study provides a systematic review of the literature (MEDLINE search with icodextrin as the keyword). Results. Icodextrin induces sustained transcapillary ultrafiltration during long dwell periods. It also stimulates increased removal of sodium by the peritoneal...

Icodextrin allergy in a peritoneal dialysis patient.

EXTRANEAL (icodextrin) peritoneal dialysis solution Label

WARNING: UNRECOGNIZED HYPOGLYCEMIA RESULTING FROM DRUG-DEVICE INTERACTION See full prescribing information for complete boxed warning • Use of non-specific glucose monitors has resulted in falsely elevated glucose readings due to maltose interference leading to inappropriate insulin administration or withholding of hypoglycemia treatment. Permanent neurological damage and death have been report...